Systems announced the signing of an agreement with a global pharmaceutical company. The agreement is intended for KORU ...

KORU Medical Systems, Inc. ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric ...

The Insignis Syringe Infusion System is a robust ... effective for patients requiring subcutaneous immunoglobulin (SCIg) for Primary or Secondary Immune Deficiency and neuromodulation therapies.

About the Insignis Infusion System The Insignis Syringe Infusion ... effective for patients requiring subcutaneous immunoglobulin (SCIg) for Primary or Secondary Immune Deficiency and ...

(Takeda) is pleased to announce that Héma-Québec has added HyQvia ® – (normal immunoglobulin [human] 10% and recombinant human hyaluronidase solution for subcutaneous infusion) as a ...

Systems (NASDAQ: KRMD), a medical technology firm with a market capitalization of $194 million, announced a partnership with a global pharmaceutical manufacturer to conduct a Phase III clinical trial.

With 40 years of expertise in subcutaneous medication delivery, our design team has developed capabilities for infusing large volumes with shorter infusion times, reducing pain and discomfort for ...

Sci的股票在汉堡证券交易所挂牌交易。 Sci的股票代码是什么？ Sci的股票代码是“SCIG。” Sci有分红吗？当前的股息收益率是多少？ Sci的股息收益率是2.84%。 Sci的市值是多少？ 截至今天，Sci的市值是7.79M。 Sci的每股收益(EPS)是多少？ Sci的每股收益(EPS)是0.928。

Some of the most common indications for IVIG are: Related: Treating MS With Intravenous Immunoglobulin (IVIG) IVIG therapy is given as an IV infusion. This means a healthcare professional will ...

Takeda Canada Inc. (Takeda) is pleased to announce that Héma-Québec has added HyQvia®– (normal immunoglobulin [human] 10% and ...